Clinical Trial Update: Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 randomized trial comparing erlotinib to pemetrexed as second-line therapy for advanced non-small cell lung cancer with adenocarcinoma histology; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Si-Yu Wang | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-09-15